Clerk of the House of Representatives Legistative Resource Center B-106 Caanon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE
99 AUG 16 AM 11: 08

H.D.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

I. Registrant Name Canfield & Associates, Inc.		,
	Suite 625 DC 20004	
Principal Place of Business (if different from line 2) City Same State/Zip (or Country)		
i. Contact Name Telephone E-ms April Boston (202) 661-2100 apri	ii (opiional) l@canfieldassoc.com	5. Senate 10 # 7997-00125
. Client Name () Self Pfizer, Inc.		6. House ID 4 3359-2009
Check if this is a Termination Report		11. No Lobbying Activity:
12. Lobbying Firms	13. Orga	anizations
NCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:	
æss than \$10,000 ()	Less than \$10,000 []	
10,000 or more	\$10,000 or more 📋 >> \$	(Esponses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
	☐ Method A. Reporting amounts using LDA definitions only ☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
	Method C. Reporting amou Internal Revenue	nts under section 162(e) of the c Code
gnature		/13/99
Printed Name and Title Anne Cauffeld - President		Page 1 of

Reg	istrant Name:	Canfield & Associates, Inc.		
Clic	nt Name:	Pfizer, Inc.		
enge	aged in lobbyin	IVITY. Select as many codes as necessary g on behalf of the client during the reporting tested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant g period, Using a separate page for each code, provide	
	R&D tax cre	ying issues nancial Freedom Act of 1999, Provisions	related to Medicare prescription drug coverage.	
17.		ongress and Federal agencies contacted Representatives	☐ Check if None	·
18.	Name of each	individual who acted as a lobbyist in this is	sue area Covered Official Position (if applicable)	New
				New
	Name	er -		
	Name Blauwet, Rog	ĐT .		No
	Name Blauwet, Ros Boston, Apri	ĐT .		No No
	Name Blauwet, Ros Boston, Apri	ĐT .		No No
	Name Blauwet, Ros Boston, Apri	ĐT .		No No
	Name Blauwet, Rog Boston, Apri Cantield, An	ĐT .	Covered Official Position (if applicable)	No No
19:	Name Blauwet, Rog Boston, Apri Cantield, An	er 3e	Covered Official Position (if applicable) on line 16 above Check if None	No No
19: Sign	Name Blauwet, Rog Boston, Apri Canfield, An	er 3e	on line 16 above Check if None Date 8/13/99	No No